Terms: = Leukemia AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
622 results:
1. jak2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid leukemia Treated with Imatinib.
Wijaya I; Bashari MH; Reniarti L; Rahmawati A; Roesli RMA
Dis Markers; 2024; 2024():2906566. PubMed ID: 38716474
[TBL] [Abstract] [Full Text] [Related]
2. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.
Ferrer-Marín F; Hernández-Boluda JC; Alvarez-Larrán A
Br J Haematol; 2024 May; 204(5):1605-1616. PubMed ID: 38586911
[TBL] [Abstract] [Full Text] [Related]
3. Extensive Hepatic Infarction due to Polycythemia Vera.
Furukawa K; Urano F; Okamura S; Kawashima H
J Gastrointestin Liver Dis; 2024 Mar; 33(1):18. PubMed ID: 38554424
[TBL] [Abstract] [Full Text] [Related]
4. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
Cheng Q; Tang Y; Liu F; Li X; Fang D
Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
[TBL] [Abstract] [Full Text] [Related]
6. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
7. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
8. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Palandri F; Palumbo GA; Benevolo G; Iurlo A; Elli EM; Abruzzese E; Polverelli N; Tiribelli M; Auteri G; Tieghi A; Caocci G; Binotto G; Cavazzini F; Branzanti F; Beggiato E; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Scaffidi L; Venturi M; Duminuco A; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Trawinska MM; Vianelli N; Cavo M; Bonifacio M; Breccia M
Cancer; 2024 Apr; 130(8):1270-1280. PubMed ID: 38153814
[TBL] [Abstract] [Full Text] [Related]
9. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract] [Full Text] [Related]
10. DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML.
Zhang X; Zhang K; Zhang J; Chang W; Zhao Y; Suo X
Eur J Haematol; 2024 Mar; 112(3):439-449. PubMed ID: 37950514
[TBL] [Abstract] [Full Text] [Related]
11. CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
Al Barashdi MAS; Ali A; McMullin MF; Mills K
Ann Hematol; 2024 Jan; 103(1):73-88. PubMed ID: 37917373
[TBL] [Abstract] [Full Text] [Related]
12. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting jak2/STAT pathway.
Mao F; Gao L; Liu L; Tang Y
J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
[TBL] [Abstract] [Full Text] [Related]
13. [Chronic neutrophilic leukemia/chronic eosinophilic leukemia].
Kawashima I; Kirito K
Rinsho Ketsueki; 2023; 64(10):1326-1334. PubMed ID: 37914248
[TBL] [Abstract] [Full Text] [Related]
14. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
15. Moving toward disease modification in polycythemia vera.
Bewersdorf JP; How J; Masarova L; Bose P; Pemmaraju N; Mascarenhas J; Rampal RK
Blood; 2023 Nov; 142(22):1859-1870. PubMed ID: 37729609
[TBL] [Abstract] [Full Text] [Related]
16. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
[TBL] [Abstract] [Full Text] [Related]
17. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Pastore F; Gittinger H; Raab S; Tschuri S; Ksienzyk B; Konstandin NP; Schneider S; Rothenberg-Thurley M; Horny HP; Werner M; Sauerland MC; Amler S; Görlich D; Berdel WE; Wörmann B; Braess J; Hiddemann W; Tischer J; Herold T; Metzeler KH; Spiekermann K
Br J Haematol; 2023 Sep; 202(6):1165-1177. PubMed ID: 37455345
[TBL] [Abstract] [Full Text] [Related]
18. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
Stahl M; Giblin G; Liu Y; Winer ES; Garcia JS; Chen E; Wadleigh M; Ling K; Lindsley RC; Shimony S; Copson K; Charles A; DeAngelo DJ; Stone RM; Nohria A; Luskin MR
Leuk Res; 2023 Sep; 132():107351. PubMed ID: 37451200
[TBL] [Abstract] [Full Text] [Related]
19. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J; Migliaccio AR; Kosiorek H; Bhave R; Palmer J; Kuykendall A; Mesa R; Rampal RK; Gerds AT; Yacoub A; Pettit K; Talpaz M; Komrokji R; Kremyanskaya M; Gonzalez A; Fabris F; Johnson K; Dougherty M; McGovern E; Arango Ossa J; Domenico D; Farnoud N; Weinberg RS; Kong A; Najfeld V; Vannucchi AM; Arciprete F; Zingariello M; Falchi M; Salama ME; Mead-Harvey C; Dueck A; Varricchio L; Hoffman R
Clin Cancer Res; 2023 Sep; 29(18):3622-3632. PubMed ID: 37439808
[TBL] [Abstract] [Full Text] [Related]
20. MAPK-negative feedback regulation confers dependence to jak2
Kesarwani M; Kincaid Z; Azhar M; Menke J; Schwieterman J; Ansari S; Reaves A; Deininger ME; Levine R; Grimes HL; Azam M
Leukemia; 2023 Aug; 37(8):1686-1697. PubMed ID: 37430058
[TBL] [Abstract] [Full Text] [Related]
[Next]
